BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Baxter Declares Quarterly Dividend - May 6, 2025

  May 7, 2025

   · 

  1 min read
• Press Releases

  Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 6, 2025

  May 7, 2025

   · 

  3 min read
• Press Releases

  Bluejay Therapeutics Reports First Preclinical Data for Liver-Targeted Fatty Acid Synthase (FASN) Inhibitor BJT-188 Being Investigated for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  May 7, 2025

   · 

  5 min read
• Press Releases

  Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis

  May 7, 2025

   · 

  9 min read
• Press Releases

  Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher

  May 7, 2025

   · 

  3 min read
• Press Releases

  Spago Nanomedical Interim Report January-March, 2025

  May 7, 2025

   · 

  5 min read
• Press Releases

  Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

  May 7, 2025

   · 

  4 min read
• Press Releases

  PharmaNest to Present Five Digital Pathology and AI Communications at EASL 2025, Showcasing Advances in Fibrosis and Inflammation Research

  May 7, 2025

   · 

  2 min read
• Press Releases

  FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

  May 7, 2025

   · 

  7 min read
• Press Releases

  Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)

  May 7, 2025

   · 

  5 min read